Intelgenx technologies corporation stock is down -100% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 64.71% of the previous 16 December’s closed higher than November.
IntelGenx Technologies Corp. focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use. INT0043/2015, an oral film containing montelukast for treatment of Alzheimer, and INT0027/2011 to treat opioid addition. The company has licensing, development, and supply agreement with Tilray, Inc. and Cynapsus Therapeutics Inc.